COVID-19 vaccine trials: The use of active controls and non-inferiority studies

BACKGROUND: Recently emerging results from a few placebo-controlled randomized trials of COVID-19 vaccines revealed estimates of 62%–95% relative reductions in risk of virologically confirmed symptomatic COVID-19 disease, over approximately 2-month average follow-up period. Additional safe and effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, Thomas R, Krause, Philip R, Nason, Martha, Longini, Ira M, Henao-Restrepo, Ana-Maria M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172418/
https://www.ncbi.nlm.nih.gov/pubmed/33535811
http://dx.doi.org/10.1177/1740774520988244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172418/
https://www.ncbi.nlm.nih.gov/pubmed/33535811
http://dx.doi.org/10.1177/1740774520988244

Ejemplares similares